CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients (Q2867196): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: budget (P474): 492,223.04 euro) |
(Changed an Item: modifying budgets in portugal one item from slovenia) |
||||||
| Property / budget | |||||||
499,557.0 Euro
| |||||||
| Property / budget: 499,557.0 Euro / rank | |||||||
Normal rank | |||||||
| Property / EU contribution | |||||||
492,223.0 Euro
| |||||||
| Property / EU contribution: 492,223.0 Euro / rank | |||||||
Normal rank | |||||||
| Property / co-financing rate | |||||||
98.53 percent
| |||||||
| Property / co-financing rate: 98.53 percent / rank | |||||||
Normal rank | |||||||
Revision as of 13:40, 21 October 2021
Project Q2867196 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients |
Project Q2867196 in Portugal |
Statements
492,223.0 Euro
0 references
499,557.0 Euro
0 references
98.53 percent
0 references
1 April 2020
0 references
31 December 2020
0 references
LIMM THERAPEUTICS, SOCIEDADE ANÓNIMA
0 references
40°21'55.76"N, 8°39'29.95"W
0 references
O projeto apresentado pela LiMM Therapeutics pretende avaliar a possibilidade de desenvolvimento de NRIL01 (reprogramadores neuronais de linfócitos inatos) na presença de SARS-CoV-2, contribuindo desta forma para minimizar as patologias renais como consequência da infeção com este vírus. (Portuguese)
0 references
The project presented by LIMM Therapeutics aims to evaluate the possibility of developing NRIL01 (neurnal reprogrammers of innate lymphocytes) in the presence of SARS-CoV-2, thus contributing to minimising renal pathologies as a consequence of infection with this virus. (English)
7 July 2021
0 references
Cantanhede
0 references
Identifiers
CENTRO-01-02B7-FEDER-069917
0 references